Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib for Type I Neurofibromatosis
NCT06620354Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of selumetinib in neurofibromatosis type 1 (NF1), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Objective Response Rate at 2 years. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on NCT06620354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06620354.